YGYechiel N. Gellman

Yechiel N. Gellman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yechiel N. Gellman has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recombinant Human Amelogenin Protein Enhances Healing of Osteochondral Injury in a Goat Model

    by Omer Helwa‐Shalom, Hani Nevo, Tarek Nasrawy, Masha Galiner, Azraq Yusef, Keren Ben‐David, Shany Ivon Markowitz, Yechiel N. Gellman, Shaul Beyth, Hagit Sacks, et al.

    Osteochondral injuries are common, painful, and lack natural healing abilities. Previous studies demonstrated that recombinant human amelogenin promotes osteochondral repair in rat knee injuries, including improved defect filling and formation of hyaline cartilage. Here, we aimed to evaluate the efficacy and safety of Remelix®, a novel recombinant human amelogenin–based product, in a large animal goat model. Acute osteochondral injuries were created in the weight‐bearing region of the medial femoral condyle in thirteen goats. Seven goats received Remelix® at a protein concentration of 0.5 mg/mL, with the contralateral knee applied with PX 407 carrier alone. An additional six goats received Remelix® at 0.25 mg/mL, while contralateral knees were treated with normal saline. Potential adverse effects, along with evaluation of osteochondral healing were assessed. Healing was assessed 24 weeks post‐treatment using magnetic resonance imaging (MRI), macroscopic evaluation, and histological and immunohistochemical analyses. No adverse effects were observed. Both Remelix® concentrations resulted in substantial healing of cartilage and subchondral bone. Histological analyses demonstrated improved tidemark formation, predominantly hyaline cartilage filling in the deeper layers of the defect with extension toward the superficial zone, and reduced subchondral bone abnormalities. MRI and macroscopic evaluations revealed a continuous repair surface with good integration at the defect margins. In contrast, PX 407 and saline‐treated control knees exhibited inferior repair, characterized by mainly fibrous cartilage, heterogeneous MRI signal intensity, and lower histological scores. Overall, Remelix® substantially improved osteochondral healing in a goat model without observable adverse effects, supporting its potential for further evaluation in human clinical studies.

  • Open Access

    Recombinant Human Amelogenin Protein Enhances Tendon‐To‐Bone Healing in a Rat Rotator Cuff Tear Model

    by Shany Ivon Markowitz, Shlomi Bulkowstein, Michael Emanuel, Oleg Dolkart, Yariv Goldstein, Omer Helwa‐Shalom, Chen Yochanan, Yechiel N. Gellman, Anat Blumenfeld, Hani Nevo, et al.

    Rotator cuff tears (RCTs) often require surgical intervention; however, surgical outcome is frequently insufficient due to poor healing of the tendon‐bone enthesis, leading to high retear rates. Previously, the recombinant human amelogenin protein (rHAM + ) regenerated injured or diseased musculoskeletal tissues including ligaments and osteochondral injuries. We therefore hypothesized that rHAM + can also induce regeneration of the biomechanical and structural properties of the enthesis. The right shoulder infraspinatus tendon of 75 rats was fully‐transected, and treated either with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) carrier ( n  = 30), or with PGA carrier alone ( n = 30). Fifteen unoperated rats were additionally evaluated. Four‐ and eight‐weeks posttreatment, the degree of regeneration was evaluated using biomechanical and histological analyses. rHAM + induced full recovery of biomechanical properties 8 weeks posttreatment, with the transected tendon demonstrating similar averaged tensile strength as the unoperated contralateral tendon, while PGA brought about substantially inferior biomechanical outcome. Eight weeks after treatment with rHAM + , progressive structural improvement was observed, including parallel type I collagen fibers with orientation and width similar to the uninjured group, restoration of the fibrocartilage zone, bone ingrowth, and a detectable tidemark, contrary to poor tissue maturation of the PGA‐treated tendons. Furthermore, rHAM + led to significantly less fatty degeneration of the infraspinatus muscle compared to PGA. rHAM + induced regeneration of biomechanical strength and promoted maturation of the enthesis of fully transected rat RCT. Therefore, we recommend further evaluation of amelogenin as possible adjunct therapeutic strategy to improve the healing and reduce retears in clinical RC repair.


  • Open Access

    Amelogenin Null Mice Develop Osteoarthritis, While Its Application Mitigates Disease Phenotypes in a Rat Model

    by Omer Helwa‐Shalom, Yarden Kahlon‐Suki, Shany Ivon Markowitz, Koby Goren, Dekel Shilo, Shira Schoonmaker, Chen Yochanan, Yechiel N. Gellman, Shaul Beyth, Dan Deutsch, et al.

    Previous studies have demonstrated that recombinant human amelogenin protein (rHAM + ) promotes healing of injured articular cartilage, subchondral bone, and skeletal ligaments. Therefore, we speculated that amelogenin may play a role in osteoarthritis (OA) development. Aged amelogenin‐null and wild‐type mice underwent micro‐computed tomography (micro‐CT) and histological analyses to assess OA‐related changes. Additionally, OA was induced in rat knees via destabilization of the medial meniscus, followed by treatment with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) or PGA alone. Magnetic resonance imaging (MRI) and histological analyses were performed. Twenty‐three‐month‐old amelogenin‐null mice exhibited severe OA features, including cartilage loss, joint space narrowing, and osteophyte formation, whereas wild‐type mice showed only mild, age‐related changes. OA pathology was evident in 12‐month‐old amelogenin‐null mice, by increased matrix metalloproteinase‐13 (MMP‐13) and decreased type II collagen expression. In osteoarthritic rats, MRI analyses demonstrated that treatment with rHAM + delayed disease progression and improved OA phenotypes. Twenty‐four weeks posttreatment, the levels of type II collagen increased, while MMP‐13 and type X collagen decreased. MMP‐13 reduction was detected as early as 2 weeks posttreatment, contributing to cartilage preservation. Furthermore, similar to the known effect of rHAM + in acute injuries, recruitment of CD105‐positive mesenchymal stem cells to the cartilage was detected 5 days posttreatment. Lack of amelogenin led to the development of osteoarthritic phenotypes, whereas in the induced osteoarthritis model, a single application of amelogenin inhibited joint deterioration and partially healed osteoarthritic damage compared with the control. These findings highlight the potential of amelogenin as a disease‐modifying agent for OA.


  • Open Access

    Regeneration of injured articular cartilage using the recombinant human amelogenin protein

    by Omer Helwa-Shalom, Faris Saba, Elad Spitzer, Salem Hanhan, Koby Goren, Shany I. Markowitz, Dekel Shilo, Nissim Khaimov, Yechiel N. Gellman, Dan Deutsch, et al.

    Aims: Cartilage injuries rarely heal spontaneously and often require surgical intervention, leading to the formation of biomechanically inferior fibrous tissue. This study aimed to evaluate the possible effect of amelogenin on the healing process of a large osteochondral injury (OCI) in a rat model.Methods: A reproducible large OCI was created in the right leg femoral trochlea of 93 rats. The OCIs were treated with 0.1, 0.5, 1.0, 2.5, or 5.0 μg/μl recombinant human amelogenin protein (rHAM+) dissolved in propylene glycol alginate (PGA) carrier, or with PGA carrier alone. The degree of healing was evaluated 12 weeks after treatment by morphometric analysis and histological evaluation. Cell recruitment to the site of injury as well as the origin of the migrating cells were assessed four days after treatment with 0.5 μg/μl rHAM+ using immunohistochemistry and immunofluorescence.Results: A total of 12 weeks after treatment, 0.5 μg/μl rHAM+ brought about significant repair of the subchondral bone and cartilage. Increased expression of proteoglycan and type II collagen and decreased expression of type I collagen were revealed at the surface of the defect, and an elevated level of type X collagen at the newly developed tide mark region. Conversely, the control group showed osteoarthritic alterations. Recruitment of cells expressing the mesenchymal stem cell (MSC) markers CD105 and STRO-1, from adjacent bone marrow toward the OCI, was noted four days after treatment.Conclusion: We found that 0.5 μg/μl rHAM+ induced in vivo healing of injured articular cartilage and subchondral bone in a rat model, preventing the destructive post-traumatic osteoarthritic changes seen in control OCIs, through paracrine recruitment of cells a few days after treatment.Cite this article: Bone Joint Res 2023;12(10):615–623.


  • Open Access

    Closed second metatarsal head intra-articular fractures: Case series and review of literature

    by Alona Katzir, Daniel Pollack, Amir Haze, Ofer Elishoov, Yechiel N. Gellman

  • Open Access

    Predictors and outcomes of diabetic foot ulcer infection with ESBL-producing bacteria in a large tertiary center

    by Michal Leibovitch, Avivit Cahn, Yechiel N. Gellman, Amir Haze, Shahar Peled, Sharon Amit, Ofer Elishoov, Karen Olshtain-Pops


  • Treatment of diabetic foot ulcers in a frail population with severe co-morbidities using at-home photobiomodulation laser therapy: a double-blind, randomized, sham-controlled pilot clinical study

    by Amir Haze, Lilach Gavish, Ofer Elishoov, Dorit Shorka, Tamir Tsohar, Yechiel N. Gellman, Meir Liebergall

    Purpose To evaluate the safety and efficacy of an at-home photobiomodulation (PBM) device for the treatment of diabetic foot ulcers (DFUs) in a frail population with severe comorbidities. Methods Prospective, randomized, double-blind, sham-controlled pilot study. Patients (age = 63 ± 11 years, male:female 13:7) with insulin-dependent diabetes type 2, neuropathy, peripheral artery disease, significant co-morbidities, and large osteomyelitis-associated DFUs (University of Texas grade ≥ III) were randomized to receive active (n = 10) or sham (n = 10) at-home daily PBM treatments (pulsed near-infrared 808 nm Ga-Al-As laser, 250 mW, 8.8 J/cm2) for up to 12 weeks in addition to standard care. The primary outcome was the %wound size reduction. The secondary was adverse events. Results With the numbers available, PBM-treated group had significantly greater %reduction compared to sham (area [cm2], baseline vs endpoint: PBM 10[20.3] cm2 vs 0.2[2.4] cm2; sham, 7.9 [12.0] cm2 vs 4.6 [13.8] cm2, p = 0.018 by Mann–Whitney U test). Wound closure > 90% occurred in 7 of 10 PBM-treated patients but in only 1 of 10 sham patients (p = 0.006). No adverse device effects were observed. Conclusions Photobiomodulation at home, in addition to standard care, may be effective for the treatment of severe DFUs in frail patients with co-morbidities and is particularly relevant at these times of social distancing. Our preliminary results justify the conduction of a larger clinical trial. ClinicalTrials.gov: NCT01493895.


  • Outcome of femoral fractures in poliomyelitis patients

    by Yechiel N. Gellman, Amal Khoury, Meir Liebergall, Rami Mosheiff, Yoram A. Weil

    As patients who were afflicted with poliomyelitis during the outbreaks in the past are aging, lower extremity osteoporotic fractures are becoming more frequent. Fixation in deformed, porotic bone, coupled with muscle weakness and imbalance creates a unique challenge when treating these fractures as does their reduced rehabilitation potential. The aim of this study was to investigate the outcome of femoral fractures in surviving poliomyelitis patients.


  • Open Access

    Closed Humeral Fracture Complicated with Acute Hematogenous Osteomyelitis: A Case Report

    by Yechiel N Gellman, Madi El-Haj, Amal Khoury, Yoram A Weil

    Acute hematogenous osteomyelitis (AHO) has been noted mainly in open fractures injuring soft tissue immunological defenses and in immuneincompetent patients. Osteomyelitis complicating closed fractures in immunocompetent adult patients is, therefore, a rare clinical entity with scarce literature. We report a case of primary Staphylococcus aureus bacterial infection of a closed, humeral shaft fracture occurring in a previously healthy 28-year-old male patient. The patient was involved in a motorcycle accident and was admitted to the surgical ward with a chest drain. While hospitalized, a peak of fever was noted, but no source was found. Diagnosis of the closed fracture infection was noted on primary open reduction and internal fixation (ORIF), and although the patient was treated with antibiotics, local osteomyelitis developed. Treatment including serial debridements utilizing gentamycin beads and an additional ORIF procedure until the full union was achieved. The patient regained full, painless, motion of the arm and shoulder. Although AHO complicating a closed fracture in immunocompetent adults is very rare, it should not be overlooked, and special attention should be sought in such cases. Meticulous debridement and rigid fixation are utmost for the eradication of infection and fracture union. Patients presenting with such infections should, therefore, be followed closely and treated promptly.